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Introduction: Chronic inflammation combined with glucocorticoid treatment and immobilization puts juvenile
idiopathic arthritis (JIA) patients at risk of impaired growth and reduced bone mineral density (BMD). Conventional
methods for evaluating bone age and BMD are time-consuming or come with additional costs and radiation
exposure. In addition, an automated measurement of bone age and BMD is likely to be more consistent than visual
evaluation. In this study, we aimed to evaluate the feasibility of an automated method for determination of bone
age and (cortical) bone mineral density (cBMD) in severely affected JIA patients. A secondary objective was to
describe bone age and cBMD in this specific JIA population eligible for biologic treatment.
Methods: In total, 69 patients with standard hand radiographs at the start of etanercept treatment and of calendar
age within the reliability ranges (2.5 to 17 years for boys and 2 to 15 years for girls) were extracted from the Dutch
Arthritis and Biologicals in Children register. Radiographs were analyzed using the BoneXpert method, thus
automatically determining bone age and cBMD expressed as bone health index (BHI). Agreement between
measurements of the left- and right-hand radiographs and a repeated measurement of the left hand were assessed
with the intraclass correlation coefficient (ICC). Regression analysis was used to identify variables associated with
Z-scores of bone age and BHI.
Results: The BoneXpert method was reliable in the evaluation of radiographs of 67 patients (radiographs of 2
patients were rejected because of poor image quality). Agreement between left- and right-hand radiographs
(ICC = 0.838 to 0.996) and repeated measurements (ICC = 0.999 to 1.000) was good. Mean Z-scores of bone age
(−0.36, P = 0.051) and BHI (−0.85, P < 0.001) were lower compared to the healthy population. Glucocorticoid use was
associated with delayed bone age (0.79 standard deviation (SD), P = 0.028), and male gender was associated with a
lower Z-score of BHI (0.65 SD, P = 0.021).
Conclusions: BoneXpert is an easy-to-use method for assessing bone age and cBMD in patients with JIA, provided
that radiographs are of reasonable quality and patients’ bone age lies within the age ranges of the program.
The population investigated had delayed bone maturation and lower cBMD than healthy children.* Correspondence: c.m.nusman@amc.uva.nl
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Chronic inflammatory diseases such as juvenile idiopathic
arthritis (JIA) can influence bone development. Conti-
nuous exposure to inflammatory cytokines, together with
glucocorticoid therapy, affects bone formation. This com-
bined with decreased physical activity and pubertal delay
puts JIA patients at risk of impaired growth and reduced
bone mineral density (BMD) [1,2]. The pediatric rheuma-
tologist needs to be aware of both the bone age and the
BMD of JIA patients in order to take this into account in
choosing the best therapy.
The assessment of bone age is usually made using the
Greulich and Pyle atlas [3]. Dual-energy X-ray densito-
metry (DXA) is the most commonly used method of
assessing BMD [4]. Recently, BoneXpert was developed,
bringing back the use of radiogrammetry, one of the
oldest methods for assessing BMD [5]. This new digital
X-ray radiogrammetry (DXR) method combines the as-
sessment of bone age with a radiogrammetric measure-
ment of (cortical) BMD (cBMD) of the second to fourth
metacarpal joints. The cBMD is expressed by BoneXpert
as a Bone Health Index (BHI), in which cBMD is cor-
rected for size. The BoneXpert method makes use of
conventional radiographs of the hand, thereby making it
attractive for pediatric use because of its simple applica-
tion, relatively low costs [6]) and lower effective radi-
ation dose compared with other methods. Normative
data are available because the method was validated in a
healthy pediatric population [7,8]. The application has
not been tested in JIA patients, in whom long-standing
inflammation of the wrist can lead to growth abnormal-
ities and destruction of the bone, thereby possibly com-
plicating the assessment of bone age and bone health.
Utilization of the Dutch Arthritis and Biologicals in
Children (ABC) register provides a unique way to eva-
luate this method in a severely affected JIA population
eligible for biologic treatment.
Our objective in this study was to evaluate the feasibility
of an automated method for the determination of bone
age and cBMD in severely affected JIA patients. A second-
ary objective was to describe bone age and cBMD in this
specific JIA population eligible for biologic therapy.
Methods
Patient selection
Patients from two centers participating in the Dutch ABC
register who were prospectively enrolled between 1999
and 2012 were eligible for this study. Biologic-naïve
patients were selected, starting etanercept, of whom a
standard radiograph of both hands and wrist in the pos-
teroanterior view was made at the start of treatment (that
is, 1 year before to 3 months after starting etanercept).
The participants’ calendar age had to be within the reli-
ability range of the BoneXpert method (that is, 2.5 to17 years for boys and 2 to 15 years for girls). Ultimately,
the radiographs of 69 patients were eligible for automatic
analysis by BoneXpert. A flowchart of the patient selection
is provided in Additional file 1.
Clinical data collection
The ABC register, a multicenter, prospective, observa-
tional study, aimed to include all children diagnosed
with JIA in whom biologic treatment was being initiated.
Informed consent was obtained from all patients older
than 12 years of age, in addition to the parents or guar-
dians of all patients younger than 16 years of age. The
study protocol was centrally approved by the Medical
Ethics Committee of the Erasmus MC, and local permis-
sion was obtained from the ethical bodies in the two
other participating hospitals (Academic Medical Center
and Reade). From the ABC register, patient and disease
characteristics were collected at baseline, including data
on disease activity from the following sources: physi-
cian’s global assessment of disease activity on a visual
analogue scale (VAS) (range from 0 to 10 cm, with 0
being the best score); Childhood Health Assessment
Questionnaire (CHAQ) (range from 0 to 3, with 0 being
the best score) by patients and/or their parents, inclu-
ding global assessment of well-being and pain on a VAS
(range from 0 to 10 cm, with 0 being the best score);
number of joints with active arthritis and joints with
limited motion; and erythrocyte sedimentation rate
(ESR). Using these variables, the Juvenile Arthritis Dis-
ease Activity Score in 10 active joints (JADAS-10) was
calculated. The scale from 0 to 40 represents the simple
linear sum of the scores of the physician and parent
and/or patient global assessment, an active joint count
(up to 10 joints) and a normalized value of ESR to a 0 to
10 scale [9].
Image analysis
The stand-alone Windows product of BoneXpert (Bone-
Xpert Version 2.1.0.12; Visiana, Holte, Denmark) was used
to analyze the hand radiographs. BoneXpert automatically
generates the following outcome variables: (calendar) age,
bone age based on Greulich and Pyle, Z-scores of bone
age (compared with a healthy reference population) [10],
BHI and Z-scores of BHI [5]. BHI is based on the cortical
thickness (T) of the three middle metacarpals. In the con-
struction of BHI, metacarpal width (W) and length (L) are
also incorporated to compensate for the high variation in
stature of growing children, as expressed in the following
formula [5]:
BHI ¼ πT 1 – T=Wð Þ= LWð Þ0:33
The radiographs included the complete hand and wrist
joints of both the left and right sides. All images were
Table 1 Patient and disease characteristics at start of
etanercept therapya
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If the radiographs were available only on conventional
films, they were digitized with a Sierra Plus scanner
(VIDAR Systems, Herndon, VA, USA) and converted to
a 300-dpi DICOM file. During the analytical process in
BoneXpert, possible error messages were noted. The
left-hand radiograph was uploaded and analyzed in
BoneXpert a second time in order to be able to deter-
mine its test–retest reliability.Baseline characteristics N = 67 patients
Females, n (%) 36 (54)
Age at onset JIA in years, mean (±SD) 8.5 (±3.8)
Age at start etanercept in years, mean (±SD) 11.0 (±3.1)
JIA disease duration before start etanercept in
years, median (IQR)
1.8 (1.1 to 3.8)
ANA-positive, n (%) 14 (21)
Category JIA, n (%)
Systemic JIA 4 (6)
Polyarticular RF-negative 27 (40)
Polyarticular RF-positive 9 (13)
Oligoarticular extended 18 (27)
Psoriatic arthritis 5 (8)
Enthesitis-related arthritis 4 (6)
Previously used medications, n (%)
Systemic prednisone 32 (48)
Methotrexate 66 (99)
DMARD other than MTX 14 (21)Statistical analysis
Descriptive statistics are reported in terms of absolute
numbers, median and interquartile range (IQR) or mean
and standard deviation (SD). The single measure intra-
class correlation coefficient (ICC) and Bland-Altman
plots were used to determine the agreement of the out-
come variables of the BoneXpert method.
To determine whether the Z-score of bone age and
the Z-score of BHI were different from those in the
healthy population, a one sample t-test was used. Uni-
variate linear regression analysis was performed to
identify variables associated with the Z-score of bone
age and the Z-score of BHI. Because of the small sample
size, only a limited number of variables could be tested.
The prespecified variables entered into the univariate
model were age, sex, JADAS-10, disease duration and
use of systemic glucocorticoids, defined as “ever use” or
“never use.” All analyses were performed with SPSS ver-
sion 20 software (SPSS, Chicago, IL, USA).Concomitant comedication at start of biologic
therapy, n (%)
Systemic prednisone 26 (39)
Methotrexate 64 (96)
DMARD other than MTX 2 (3)
Disease activity parameters at baseline, median (IQR)
Physician-rated VAS (0 to 10 cm; best score = 0) 6.5 (5.0 to 7.4)
CHAQ total (0 to 3; best score = 0) 1.50 (0.90 to 2.10)
VAS pain (0 to 10 cm; best score = 0) 6.3 (2.4 to 7.7)
VAS well-being (0 to 10 cm; best score = 0) 6.1 (3.2 to 7.4)
Active joints 11 (7 to 18)
Limited joints 6 (3 to 13)
ESR 11 (5 to 29)
JADAS-10 (0 to 40), mean (±SD) 21 (±5)
Ever hand or wrist involvement, n (%) 64 (96)
Z-score of BA, mean (±SD) −0.36 (±1.44)
Z-score of BHI, mean (±SD) −0.85 (±1.15)b
aANA, Antinuclear antibody; BA, Bone age; BHI, Bone Health Index; CHAQ, Child
Health Assessment Questionnaire; DMARD, Disease-modifying antirheumatic
drug; ESR, Erythrocyte sedimentation rate; JADAS, Juvenile Arthritis Disease
Activity Score; JIA, Juvenile idiopathic arthritis; MTX, Methotrexate;
RF, Rheumatoid factor; VAS, Visual analogue scale; Z-score, Standard
deviation compared with healthy population. bSignificantly different from 0
at the P < 0.05 level.Results
Feasibility
A standard hand radiograph of both hands was available
for 69 patients starting etanercept treatment. The calcu-
lations of bone age and BMD by BoneXpert took a few
seconds. BoneXpert rejected the radiographs of two
patients because of poor image quality, resulting in avail-
able BoneXpert outcomes of 67 patients. In three pa-
tients, an error message indicating uncertainty of bone
age was given by BoneXpert; these patients had calendar
ages within the BoneXpert age ranges (2.5 to 17 years
for boys and 2 to 15 years for girls), but their bone age
came out of the analysis to be outside these age ranges,
resulting in an error message. However, BoneXpert pro-
duced all outcome variables in these three patients, ex-
cept for a missing Z-score of BHI in one patient.
The ICC of the agreement of all outcome variables
between the left and right hand radiographs varied from
0.838 to 0.996. Bland-Altman plots of the agreement
between left- and right-hand radiographs are provided in
Additional file 2. The ICC of the agreement of repeated
measurements of all left-hand radiographs on Z-scores
of bone age and BHI varied from 0.999 to 1.000.Patient and disease characteristics
Patient and disease characteristics of the 67 patients
who could be evaluated with BoneXpert are presented in
Table 1. Disease activity of these patients was moderate
to severe at the time the hand radiographs were made
(mean JADAS-10 score = 21 ± 5).
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mal population, but not significantly (mean Z-score of
bone age = −0.36 (±1.44), P = 0.051). Bone maturation
was greatly impaired (below −2 standard deviations
(SD)) in eight patients, and three patients had highly
accelerated bone maturation (above +2 SD). The mean
Z-score of bone age was strongly influenced by one pa-
tient with a very high bone age (+5 SD), who had long-
standing severe polyarticular enthesitis-related arthritis.
When this patient was left out of the analysis, the mean
bone maturation of the remaining patients was sig-
nificantly delayed (mean Z-score of bone age = −0.45
(±1.28), P = 0.008). Compared with the normal popula-
tion, the cBMD was lower (mean Z-score of BHI = −0.85
(±1.15), P < 0.001). Ten patients had a Z-score of BHI
less than −2 SD.
Regression analysis
A univariate linear regression analysis of bone age and
BHI was performed to investigate which variables were
associated with the Z-score of bone age and the Z-score
of BHI (Tables 2 and 3). Glucocorticoid use was as-
sociated with a lower Z-score of bone age (0.79 SD,
P = 0.028). Only male gender was significantly associated
with the Z-score of BHI; being a boy lowered the
Z-score of BHI of 0.65 points (P = 0.021).
Discussion
Application of the BoneXpert automated method for
assessing bone age and cBMD in JIA patients proved to
be feasible. Its use was easy and fast, and the program
rejected few radiographs. The Z-scores of bone age and
BHI were found to be impaired in the population of JIA
patients evaluated in this study compared with a healthy
population.
In addition to its validation in a healthy pediatric popu-
lation [7,8], bone age measurement using BoneXpert has
been evaluated in pediatric patients of short stature,
children with precocious puberty and patients with
congenital adrenal hyperplasia [11-13]. In these patient
groups, in whom bone maturation is likely to be affec-
ted, the BoneXpert bone measurement method provedTable 2 Univariate regression coefficients of baseline variable






Ever use of systemic glucocorticoids −0.790
aCHAQ, Child Health Assessment Questionnaire; JADAS, Juvenile Arthritis Disease Ac
population.feasible. We had anticipated a higher number of rejections
by the BoneXpert program relating to growth abnormal-
ities, periarticular abnormalities and deviation of bone age
commonly found in severely affected JIA patients [14-17].
Unexpectedly, BoneXpert rejected no radiographs because
of these abnormalities. Besides the two rejections due to
poor image quality, only one radiograph with extremely
accelerated bone maturation resulted in absence of a
Z-score of BHI. The low rejection rate is advantageous;
however, one has to take into account that patients out-
side the age ranges of the program had to be excluded,
who were composed mostly of older patients (older than
15 years of age for girls and older than age 17 years for
boys). For follow-up of patients, it would be useful if a
BHI reference existed for children who have reached
skeletal maturity. Besides a low rejection rate, the method
also showed a very good agreement between left- and
right-hand assessment and two repeated measurements of
the left-hand radiograph. The excellent agreement of the
repeated measurement of one radiograph is to be ex-
pected, whereas BoneXpert is an automated computer
technique. Other methods used to determine reliability,
such as analysis of two radiographs of the same hand of
the same patient at one time point, could not be per-
formed, because these radiographs were not available.
Bone maturation and cBMD were found to be impaired,
as was expected for this group of JIA patients [1,2,17]. A
regression analysis showed that delayed bone age was as-
sociated with glucocorticoid use and that lower BHI was
associated with male gender. The association between
delayed bone age and glucocorticoid use was not unex-
pected, as numerous studies have shown that glucocor-
ticoid use may slow longitudinal bone growth and growth
plate senescence [18,19]. In other earlier studies, not only
bone age but also impaired BMD has been associated with
the use of glucocorticoids [1,20,21]. In the present study,
this was not the case; the only variable in the regression
analysis significantly associated with cBMD was male
gender. The lack of association between glucocorticoid
use and cBMD could be due to the broad definition of
glucocorticoid use (that is, cumulative dose was not taken
into account) and the relatively small size of our studys with Z-scores of bone agea
95% CI P-value
−0.116 to 0.164 0.736
−0.921 to 0.541 0.605
−0.184 to 0.1234 0.694
−0.577 to 0.534 0.940
−0.065 to 0.081 0.830
−1.492 to −0.088 0.028
tivity Score; Z-score, Standard deviation score compared with healthy
Table 3 Univariate regression coefficients of baseline variables with the Z-score of Bone Health Indexa
Baseline variable Estimated β 95% CI P-value
Age 0.067 −0.024 to 0.159 0.147
Male gender −0.649 −1.197 to −0.102 0.021
Disease duration 0.040 −0.080 to 0.160 0.505
CHAQ 0.008 −0.420 to 0.436 0.971
JADAS-10 −0.036 −0.094 to 0.023 0.224
Ever use of systemic glucocorticoids −0.340 −0.904 to 0.224 0.233
aCHAQ, Child Health Assessment Questionnaire; JADAS, Juvenile Arthritis Disease Activity Score; Z-score, Standard deviation score compared with the healthy
population.
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in adults with rheumatoid arthritis have shown that gluco-
corticoids can decelerate the loss of hand BMD [22,23].
Although rheumatoid arthritis and JIA are two different
entities, a similar protective effect of glucocorticoids on
hand BMD may have played a role in our population. The
association with male gender is less easy to interpret. It
was previously shown that differences exist between
healthy boys and girls in BMD of the forearm, with boys
having higher BMD of the forearm than girls [24]. This
difference is not associated with body mass index, but is
likely to be associated with other factors. The same group
also found an association between physical activity and
BMD of the forearm, combined with the finding that boys
are more physically active than girls [25]. The difference
in BHI between boys and girls in the current studies might
therefore be explained by low physical activity due to
disease activity and by boys being relatively less phy-
sically active compared to their healthy peers than girls.
The link between physical activity and lower cortical
thickness of the forearm was also hinted at in a study in
pediatric Crohn’s disease patients. In that study, a lower
cortical thickness was also found in boys, which im-
proved with treatment, possibly because patients also
increased their daily physical activities with their re-
sponse to treatment [26].
The BoneXpert method is used to measure bone age
and BHI. With respect to bone age, the method can be
considered feasible for future use in multicenter or longi-
tudinal follow-up studies in JIA patients, because of its
easy use, high precision and small differences between
left- and right-hand radiographs [8]. Besides its application
in research, the BoneXpert method can also potentially be
of use in clinical practice. The automatic determination of
bone age and cBMD is less costly than other methods and
is time-saving for both pediatric rheumatologists and ra-
diologists. Moreover, only one hand—either right or left—
needs to be analyzed, which increases the feasibility of use
in daily practice (unless there is an extreme clinical dis-
crepancy between left and right).
The other major outcome variable, the BHI, needs
more validation studies before it can be used in researchand clinical practice. The DXR method for the assess-
ment of cBMD, used by BoneXpert, has been compared
to DXA in several patient groups, including patients
with inflammatory bowel disease [27]. In these patients,
the correlation between DXR and DXA was found to be
moderate to good. In JIA patients, however, cBMD of
the hand may be influenced by local inflammation, pos-
sibly resulting in a lower correlation with generalized
BMD, as shown in adult patients with rheumatoid arth-
ritis [28]. If BHI can be used as a proxy for generalized
BMD in JIA patients, further validation in this popula-
tion is needed, including a comparison with other BMD
measurement techniques. This is complicated by the fact
that there are different methods used to determine BMD
without consensus on the gold standard, although DXA
is the most widely utilized technique.
Limitations
This study is limited by its observational design and the
very specific population derived from the ABC register.
These factors introduce a selection bias, which limits
generalization to the full JIA population. However, pa-
tients included in the ABC register are considered to be
the most severely affected patients because of their eligi-
bility for biologic treatment; therefore, these patients are
most likely to have structural bone damage. It can be as-
sumed that if the BoneXpert method can be applied in
these patients, it can be used in all JIA patients. Most ra-
diographs used in this study were digital; however, some
conventional radiographs were included. BoneXpert
works less well with these digitized images, as demon-
strated by the two radiographs that were rejected by the
program. Given the widespread use of digital radiology
throughout Europe, this will not be a problem in future
studies.
Conclusions
To our knowledge, this study is the first in which the
BoneXpert automated determination of bone age and
cBMD has been evaluated in JIA patients. The method
proved feasible and easy to use, even in severely affected
JIA patients, provided that radiographs were of reasonable
Anink et al. Arthritis Research & Therapy 2014, 16:424 Page 6 of 7
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BoneXpert program. This method can be implemented in
clinical practice for the determination of bone age in JIA
patients. It needs further validation for the determination
of bone health, including comparison with existing
methods for the determination of BMD.
Additional files
Additional file 1: Flowchart of patient selection.
Additional file 2: Bland-Altman plots of the agreement between
left and right hands.
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